Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer. This event on Drug Discovery brings together key decision makers across the industry to discuss how drug discovery and developments can change the healthcare and pharma industry. The event will consist of Keynote session, along with panel discussion and networking session.
ML & AI Lead at Combine AI, Software Engineering, Statistics & Visualization at Pfizer
Principal Research Scientist & Group Lead Pharma Discovery AbbVie
Director, Data Science and AI at Novartis Novartis
Group Director in Drug Discovery at Bristol Myers Squibb
Director, Data Science and AI at Novartis Novartis